Form 4 for ANAB ANAPTYSBIO, INC
Accepted 2026-01-06 00:00:00 ET · period of report 2026-01-03 · accession 0001673528-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-06 | 2026-01-03 | ANAB | Faga Daniel | Pres, CEO, Dir | M - OptEx | — | +34.7K | 473.4K | +8% | — |
| D | 2026-01-06 | 2026-01-05 | ANAB | Faga Daniel | Pres, CEO, Dir | S - Sale+OE | $43.26 | -15.3K | 458.1K | -3% | -$662.3K |
| D | 2026-01-06 | 2026-01-03 | ANAB | Faga Daniel | Pres, CEO, Dir | M - OptEx | $0.00 | -34.7K | 69.4K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-03 | M | A | 34,677 | — | 473,448 | D | — | — | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. (F2) Reflects the acquisition of 2,305 shares acquired under the Company's ESPP. |
| 2 | Common | Common Stock | 2026-01-05 | S | D | 15,309 | $43.26 | 458,139 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2026-01-03 | M | D | 34,677 | $0.00 | 69,355 | D | — · — to — | 34,677 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. (F4) The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |